Conference Coverage
Latest News
Jul 27, 2026 | Opinion
Why accurate CIS diagnosis matters in bladder cancer care
Darlifarnib plus cabozantinib shows encouraging antitumor activity in ccRCC
Jul 27, 2026
Joshua Halpern, MD, MS, on the clinical role of mail-in semen analysis
Jul 27, 2026
TULSA preserves penile length vs robotic prostatectomy in CAPTAIN trial
Jul 24, 2026
The UroOnc Minute: Optimizing Patient Follow-Up in Urologic Oncology, With Jason Hafron, MD
Jul 24, 2026
Advertisement
Shorts
1:33
The UroOnc Minute: Using physician data to improve patient outcomes
3 hours ago
by
Adam B. Weiner, MD(+1 more)
1:07
Debra L. Fromer, MD, highlights efficacy data on tebipenem pivoxil for cUTI
3 days ago
by
Debra L. Fromer, MD
0:52
Beyond trial and error: The future of functional urology
4 days ago
by
Sasha Vereecken, RN
1:04
How the BRIDGE trial may impact bladder cancer treatment
5 days ago
by
Tyler Garman, MD
0:38
A new perioperative standard emerges for MIBC
6 days ago
by
María Natalia Gandur Quiroga, MD, MSc
1:15
Matthew Galsky, MD, explains the significance of perioperative EV/pembro in MIBC
7 days ago
by
Matthew Galsky, MD
0:42
From symptoms to systems: How functional urology evolved
10 days ago
by
Sasha Vereecken, RN
1:22
First Assist: The evolving role of cystectomy in bladder cancer
11 days ago
by
Taylor Goodstein, MD(+1 more)
0:42
Closing the gap: Urologists and female sexual health
12 days ago
by
Melissa Moran, DO
0:54
Testosterone and prostate cancer risk: A balanced message
13 days ago
by
Helen L. Bernie, DO, MPH
From GSM guidance to HRT reform: A landmark year for women’s health
2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.
Inguinal lymph node dissection in penile cancer
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
Inside HoLEP: Irina Jaeger, MD, discusses patient selection and technique
Jaeger emphasizes that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication.
Podcasts
Videos
Urology Times Digital Edition
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.
"If 2025 showed us anything, it is the power of combining scientific progress with public engagement," writes Michael S. Cookson, MD, MMHC, FACS.
"Once money is in a Roth IRA, the withdrawal rules depend on whether the funds are contributions, conversions, or earnings," writes Julie Khazan, CFP.
The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial.
The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.
"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.
The ENDURE 1 study plans to enroll up to 60 patients with benign ureteric strictures.
The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.
Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication
Continuing Medical Education
Advertisement
All News
Advertisement
Can Aydogdu, MD, highlights a study examining the utility of pre-surgical tumor-informed ctDNA to predict pathologic nodal status at radical cystectomy.
The PDUFA target action date is in the fourth quarter of 2026.
The study showed that perioperative EV–pembrolizumab improved EFS, OS, and pCR rate vs neoadjuvant cisplatin-gemcitabine in patients with MIBC who are eligible for cisplatin-based chemotherapy.
Experts discuss practical strategies to improve the detection of CIS through closer urologist-pathologist collaboration, optimized biopsy techniques, and complementary diagnostic tools.
Olaparib's indications in the US include use as a single agent for patients with HRR gene-mutated mCRPC and in combination with abiraterone and prednisone for patients with BRCA-mutated mCRPC.
These results provided the basis for the ongoing randomized phase 3 ProstACT Global trial evaluating 177Lu-rosopatamab tetraxetan in mCRPC.
Declan Murphy, MB, BCH, BaO, FRACS, FRCS, Urol, discusses the clinical significance of the phase 3 PROTEUS trial and addresses concerns about the study's use of ADT in the control arm.
Amy Pearlman, MD, and Larry I. Lipshultz, MD, speak with Shane Kronstedt, MD, about research on the long-term reproductive and urologic effects of military exposures and how these findings may help improve care for veterans.
Experts discuss why CIS is frequently underrecognized, highlighting the subtle clinical and cystoscopic features of the disease and the importance of integrating multiple factors to improve detection.
This marks the first phase 3 study of a targeted radiopharmaceutical therapy in clear cell renal cell carcinoma.
Advertisement
Tyler S. Garman, MD, highlights phase 2 data on intravesical gemcitabine and docetaxel as first-line treatment of BCG‒naïve NMIBC.
Results from a first-in-human phase 0 feasibility trial showed that combined bladder and kidney transplantation was technically feasible.
Kathryn H. Gessner, MD, PhD, discusses the current limitations in identifying appropriate candidates for bladder-preserving trimodal therapy, the promise of utDNA, and why shared decision-making remains essential.
A secondary analysis of the ASPIRE trial found residual stone volume—not conventional stone-free status, baseline volume, or density—is the strongest predictor of post-ureteroscopy health care utilization, with each 100-mm³ increase doubling event odds.
Department of Defense announces annual testosterone deficiency screening for service members
Published: | Updated:
The Department of Defense will begin annual testosterone deficiency screening for service members aged 30 years and older.
Advertisement
Advertisement
Trending on Urology Times
1
TULSA preserves penile length vs robotic prostatectomy in CAPTAIN trial
2
KEYNOTE-B15 data on enfortumab vedotin plus pembrolizumab in MIBC published in NEJM
3
The Unmet Need in BCG-Unresponsive NMIBC
4
Managing ARPI Toxicities and Treatment Goals in mCSPC
5